Diabetes Mellitus Clinical Trial
Official title:
Gingival Crevicular Fluid and Salivary Levels of Neuregulin-4 and Its Receptor ErbB4 in Patients With Stage III and IV Periodontitis With and Without Type 2 Diabetes: An Observational Study
NCT number | NCT04930588 |
Other study ID # | PER7-2-1 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | June 1, 2021 |
Est. completion date | December 2023 |
The aim of this study is to assess the levels of neuregulin-4 and its receptor ErbB4 in the GCF and saliva in stage III and IV periodontitis patients with and without type 2 diabetes mellitus.
Status | Recruiting |
Enrollment | 42 |
Est. completion date | December 2023 |
Est. primary completion date | June 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - For periodontitis stage III and IV patients according to (Papapanou et al., 2018 and Tonetti et al., 2018) 1. Bleeding on probing (BOP) = 30%. 2. At least four non-adjacent teeth sites in each jaw having CAL = 5 mm and PD = 6 mm in one or more sites. 3. Tooth loss due to periodontitis = 5 teeth. 4. Presence of a minimum of 15 natural teeth. For diabetes and non-diabetic patients according to ("Diagnosis and Classification of Diabetes Mellitus," 2014) 5. Patients with type 2 diabetes mellitus will be diagnosed as having type 2 diabetes mellitus = 5 years before the study and treated with stable doses of oral hypoglycaemic agents and/or insulin under the supervision of an endocrinologist with their glycated haemoglobin level (HBA1c) > 6%. 6. Non diabetic Patients in the control and stage III and IV periodontitis groups will be selected as having Fasting plasma glucose (FPG) <126 mg/dL. Exclusion Criteria: 1. Individuals with any known systemic disease other than type 2 diabetes. 2. Pregnant and lactating women. 3. Individuals that received periodontal treatment within the last 6 months. 4. Individuals with a history of systemic antibiotics and anti-inflammatory drugs within the last 3 months. 5. Former or current smokers. |
Country | Name | City | State |
---|---|---|---|
Egypt | Cairo university Faculty of dentistry | Cairo |
Lead Sponsor | Collaborator |
---|---|
Cairo University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Neuregulin-4 in the GCF | Measured by Enzyme-Linked Immunosorbent Assay in µL | 6 month | |
Primary | The receptor ErbB4 in the GCF | Measured by Enzyme-Linked Immunosorbent Assay in µL | 6 month | |
Primary | Neuregulin-4 in the saliva | Measured by Enzyme-Linked Immunosorbent Assay in µL | 6 month | |
Primary | The receptor ErbB4 in saliva | Measured by Enzyme-Linked Immunosorbent Assay in µL | 6 month | |
Secondary | Pocket depth | Measured by Manual UNC periodontal probe in mm | 6 month | |
Secondary | Clinical attachment level | Measured by Manual UNC periodontal probe in mm | 6 month | |
Secondary | Bleeding on probing | Measured by Manual UNC periodontal probe by gently probing the orifice of the gingival crevice, the periodontal probe will be inserted 1 to2 mm into the gingival sulcus starting at one interproximal area and moving to the other. If bleeding occurs within 10 seconds a positive finding is recorded. | 6 month | |
Secondary | plaque index | Measured by Manual UNC periodontal probe Scores:
0: No plaque A film of plaque adhering to the free gingival margin and adjacent area of the tooth. The plaque may be seen in situ only after application of a disclosing solution or by using the probe on the tooth surface. Moderate accumulation of soft deposits within the gingival pocket, or the tooth and gingival margin, which can be seen with the naked eye. Abundance of soft matter within the gingival pocket and/or on the tooth and gingival margin. |
6 month | |
Secondary | Glycosylated Haemoglobin (HbA1c %) | Measured by High performance liquid chromatography in mmol/mol | 6 month | |
Secondary | Fasting plasma Glucose Level (FPG) | Measured by blood sampling in (mg/dl) | 6 month | |
Secondary | Body Mass Index (BMI) | Measured in (Kg/m2) | 6 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |